Shanghai Shuyao Intelligence Submits IPO Prospectus for China's First Approved Digital Therapeutic for ADHD

In China, the overall prevalence of ADHD among children and adolescents is as high as 6%, with more than 23 million affected individuals. Given this population’s strong payment capacity, high willingness to pay, and substantial policy support, the sector has emerged as the next trillion-yuan market opportunity, attracting significant attention and strategic positioning from numerous investors.

ShuYao Intelligence’s independently developed “Attention Enhancement Training Software” has completed multi-center GCP clinical trials. Clinical outcomes have validated its efficacy, compliance, and safety in children with ADHD following a one-month intervention of attention enhancement training. As one of the first “digital therapeutics” prescribed electronically in this field, the software is indicated for adjunctive treatment and rehabilitation training in children aged 6–12 years with Attention-Deficit/Hyperactivity Disorder (ADHD), filling a gap in China’s digital therapeutics landscape for ADHD.

Artery Selection New Product Review Issue 19 InvitesLi Wenyu, CEO of Shuyao Intelligence; Jiang Kewen, Chief Physician at the Children's Hospital, Zhejiang University School of Medicine; and Zhou Chen, Chief Commercial Officer of Shuyao IntelligenceIntroducing Shuyao Intelligence's Product Overview.

This digital therapeutic product utilizes functional games as a medium to deliver direct, personalized therapeutic effects for ADHD. By leveraging the advantage of immediate feedback during gameplay, it reshapes cognitive neural networks and induces physiological changes in the brain to improve cognitive function. Featuring multitasking capabilities, adaptability, and proprietary AI algorithms, the system dynamically adjusts its state based on the user’s performance, thereby creating a personalized treatment experience. Furthermore, by analyzing training behavioral data and electroencephalogram (EEG) data, it calculates multiple performance metrics to generate professional reports, enabling physicians and parents to continuously monitor and evaluate treatment efficacy.

"Attention Training Software" innovatively combines technologies for targeted modulation of the prefrontal cortex, sensory-motor integration training, and executive function training, presented through functional game tasks to improve attentional function.

Targeted Modulation of the Prefrontal Cortex

Based on a multi-task training paradigm validated by scientific research and clinical practice, this approach can target the modulation of prefrontal cortex activation patterns and suppress the Default Mode Network (DMN), thereby improving users’ inhibitory control function and enhancing sustained attention. Furthermore, it leverages neuroplasticity mechanisms to consolidate the training effects.

Sensory-Motor Integration Training

By integrating limb movements with extensive visual, auditory, and tactile stimuli, and leveraging adaptive closed-loop algorithms to maintain optimal training difficulty, this approach simultaneously activates multiple brain regions—including the prefrontal cortex, sensory and motor cortices, basal ganglia, and cerebellum—thereby fostering cross-regional synchrony and connectivity to enhance the brain’s information processing efficiency.

Executive Function Training

Designed to target the core symptoms of ADHD (executive function deficits), a variety of training task types have been developed, covering spatial navigation, working memory, abstract calculation, motor planning, and decision-making. Clinical validation has demonstrated significant improvement in these areas.

Leveraging precise brain region targeting combined with adaptive algorithms, the product enables highly effective personalized treatment plans.

High adherence, good user experience

Children are naturally inclined toward interaction. For children with ADHD, a guiding approach is more effective than suppression. The "Attention Enhancement Training Software" uses bright and cheerful colors to create a relaxed and enjoyable digital therapeutic atmosphere, making it easier for participants to feel happy and engaged, thereby effectively improving adherence.

High safety profile, no side effects

External intervention training improves attention. GCP-compliant, multicenter clinical trials have demonstrated the product's high safety profile and absence of related adverse effects.

Pure Digital Therapeutics: Monitorable Data-Driven Efficacy

Calculate multiple training performance scores based on behavioral training data and EEG data to generate professional reports for reference by physicians and parents.

Scan the QR code on the poster to add our assistant and reserve your spot for the live broadcast!

Li Wenyu

CEO of Shuyao Intelligence

Possesses extensive experience in the development and operation of internet products. As a renowned internet product producer in the industry, he has served as Producer at Shengqu Games, Vice President of R&D at Shanghai Jinyou, and Chief Technology Officer at Shanghai Baoyu, achieving remarkable accomplishments in the technical development and operational management of internet products.

Jiang Kewen

Chief Physician, Children's Hospital Affiliated to Zhejiang University School of Medicine

Ph.D. in Pediatrics, Chief Physician, Doctoral Supervisor, Recipient of the Zhejiang Province Distinguished Young Scholars Fund, and Member of the Zhejiang “151” Talent Program. From December 2006 to January 2009, served as Visiting Associate Professor at Stanford University, USA (one of the first recipients funded by Zhejiang University’s “New Star Program”). From June 2010 to January 2011, served as Senior Visiting Scholar at Indiana University, USA. Currently serves as Standing Committee Member of the Special Committee on Novel Biomarkers under the Zhejiang Society of Mathematical Medicine, and Member of the Pediatric Neurology Group of the Pediatric Branch of the Zhejiang Medical Association. Previously served as Vice Chair of the Brain Science Committee of the Pediatric Branch of the Chinese Medical Association, and Council Member of the Zhejiang Neuroscience Society. Has presided over numerous provincial and ministerial-level research projects, including four General Programs of the National Natural Science Foundation of China, one sub-project of the National Key R&D Program, one Distinguished Young Scholars Team Project of the Zhejiang Provincial Natural Science Foundation, and one “Qianjiang Talents” Project from the Zhejiang Provincial Department of Science and Technology, among others. Has published more than 50 academic papers, with over 40 indexed by SCI. The research team primarily focuses on the pathogenesis and prevention/treatment strategies for epilepsy, neurodevelopmental disorders, and cerebral ischemic injury. Experimental techniques employed include brain slice and in vivo patch-clamp recordings, high-resolution whole-brain calcium imaging in zebrafish, genetic manipulation, and molecular biology. The team has conducted in-depth investigations into the roles of ATP-sensitive potassium channels, astrocytic conductance, GABAergic conductance, and excitatory autapses in the pathogenesis of neurodevelopmental disorders, achieving several breakthroughs.

Zhou Chen

Chief Business Officer, Shuyao Intelligence

A seasoned professional in the internet industry, previously served as Senior Manager of Public Relations and Marketing at Shanda Network (now Shengqu Games), responsible for government and media relations as well as marketing promotion. Joined Baoyu Information Technology Co., Ltd. in 2008 as Marketing Director. In 2011, returned to Shanda Games (later renamed Shengqu Games) as Director of External Cooperation and General Manager of Cooperative Projects. In 2021, joined Shanghai Shuyao Intelligent Technology Co., Ltd. as Head of Marketing and Business Development, overseeing product registration, market launch, sales partnerships, and other external affairs.

ShuYao Intelligence, established in 2021, is an innovative digital therapeutics company centered on independent research and development, and a member of the Century Huatong ecosystem. By integrating biosensor application research with artificial intelligence analysis, and leveraging cutting-edge advancements in neural network science, the company is dedicated to providing digital therapeutic solutions for the diagnosis and treatment of neurological disorders, thereby advancing the development of digital precision medicine. Meanwhile, it continuously explores effective applications of digital health across various fields to promote frontier research in neuroscience.
The Company has always upheld the spirit of proactive innovation and determined progress. Centered on clinical needs and leveraging EEG bioinformation technology and core algorithmic analysis, it develops technologies, products, and platforms tailored for digital therapeutics, pioneering efficient, convenient, and universally accessible digital therapeutic solutions. Meanwhile, Shuyao Intelligence is actively expanding into brain-computer interface (BCI)-related fields. By capitalizing on its strengths in neuroscience and open BCI software service platforms, the Company fosters collaboration and translation of research findings into practical applications within the BCI sector, thereby establishing a robust platform to facilitate integrated innovation and foundational cooperation across the industry chain.
Shuyao Intelligence has assembled a team of outstanding, multidisciplinary experts and has completed the development of a diverse portfolio of digital therapeutic products, including the “Attention Enhancement Training Software” for Attention-Deficit/Hyperactivity Disorder (ADHD), the “Autism Rehabilitation Training Software” for Autism Spectrum Disorder (ASD), and the brain-computer interface product “ShuMian.” This achievement lays a solid foundation for the broader application of digital medical technologies.
In the future, Shuyao Intelligence will continue to strengthen its scientific research and technological development. By leveraging continuous innovation in technology and products, the company aims to explore and understand the human brain, help people improve their mental health, serve society, and provide health safeguards for a better life for humanity.

“Artery Select New Product Launch” is a live-streaming program under the “Artery Select” brand, dedicated to supporting medical enterprises in launching innovative products. The program’s mission is to empower every milestone launch of innovative medical products.

Scan the QR code below to contact the assistant and schedule a live stream.

(If already added, please proactively contact the assistant)